HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Oncolytics Biotech (NASDAQ:ONCY) and maintained a $15 price target.
August 16, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $15 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $15 by HC Wainwright & Co. suggests a positive outlook for Oncolytics Biotech, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100